Although the pembrolizumab 8 arm of I-SPY2 did not have strong enough results to continue onto phase 3, it does provide some insights and highlights the need for precision medicine to tailor approaches to treatment, said Rita Nanda, MD, associate professor, medicine, The University of Chicago Medicine.
Although the pembrolizumab 8 arm of I-SPY2 did not have strong enough results to continue onto phase 3, it does provide some insights and highlights the need for precision medicine to tailor approaches to treatment, said Rita Nanda, MD, associate professor, medicine, The University of Chicago Medicine.
Transcript
Based off the results from I-SPY2 phase 2 trial, Pembro8-noAC did not appear to perform well enough to warrant a phase 3 trial. What are the next steps in treatment development for patients with early stage, high-risk HER2 negative breast cancer?
So, as you know that pembrolizumab 8 arm of I-SPY2, which removed the AC [doxorubicin and cyclophosphamide] from the last 4 cycles of therapy did not graduate. The pembrolizumab 8 arm appeared to be as effective as Taxol followed by AC, and therefore, didn't graduate, and we won't be pursuing it further.
There are, however, likely a subset of patients who don't need anthracycline-based chemotherapy. I personally had some patients who did very well on that arm of the trial. So, I think what we really need to look at in terms of the data from that trial is the biomarker work, because I think what we're hoping to move to to the future is precision medicine where we can really tailor our approaches to what any individual patient needs.
I think a lot of patients don't need as much chemotherapy as we're currently giving and may be able to de-escalate chemotherapy. I think that some patients need chemotherapy and maybe won't benefit from immune-based strategies. I think looking at the biomarker work that's going to come from I spy two will be really helpful in moving forward, how we want to plan the next generation of trials for women with early-stage HER2-negative breast cancer.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More